Published in Oncologist on March 20, 2014
Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol (2014) 1.28
Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol (2015) 0.81
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol (2015) 0.81
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol (2015) 0.78
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget (2015) 0.77
Challenges of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev (2015) 0.75
How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol (2016) 0.75
Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC Cancer (2017) 0.75
Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma". Hepatobiliary Surg Nutr (2016) 0.75
VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res Protoc (2017) 0.75
Significance of different response evaluation criteria in predicting progression-free survival of lung cancer with certain imaging characteristics. Thorac Cancer (2016) 0.75
Computed tomograpy evaluation of morphological changes, clinical response and survival in colorectal cancer liver metastasis treated by regorafenib: A case report. Mol Clin Oncol (2016) 0.75
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes (2015) 0.75
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut Liver (2017) 0.75
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol (2004) 3.38
Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS (1989) 2.59
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol (2011) 2.37
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer (2011) 2.07
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res (2011) 1.39
Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology (2011) 1.36
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25
Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol (2009) 0.90
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol (2013) 4.55
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol (2006) 4.42
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg (2005) 3.46
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol (2004) 3.40
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg (2003) 3.16
Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol (2006) 3.14
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst (2009) 2.98
Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology (2003) 2.75
Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg (2006) 2.70
Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology (2003) 2.57
A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation (2006) 2.55
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hemorrhage after pancreaticoduodenectomy: when is surgery still indicated? Am J Surg (2007) 2.44
Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study. Hepatology (2003) 2.43
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol (2005) 2.38
Changing trends in malignant transformation of hepatocellular adenoma. Gut (2011) 2.28
Benefit of laparoscopy for rectal resection in patients operated simultaneously for synchronous liver metastases: preliminary experience. Surgery (2008) 2.25
Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis. Radiology (2014) 2.22
Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg (2003) 2.20
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology (2011) 2.14
Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther (2002) 2.13
Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology (2015) 2.11
Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int (2008) 2.06
Uterine necrosis following pelvic arterial embolization for post-partum hemorrhage: review of the literature. Eur J Obstet Gynecol Reprod Biol (2013) 2.05
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol (2008) 2.01
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology (2009) 2.00
Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg (2013) 1.98
Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.98
Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol (2005) 1.94
Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology (2004) 1.92
Ischemic complications after pancreaticoduodenectomy: incidence, prevention, and management. Ann Surg (2009) 1.89
Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol (2009) 1.88
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res (2003) 1.88
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int (2011) 1.84
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl (2010) 1.81
Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology (2014) 1.81
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol (2005) 1.80
Evaluation of in silico splice tools for decision-making in molecular diagnosis. Hum Mutat (2008) 1.78
Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery (2002) 1.76
Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl (2008) 1.75
Predictors of the risk of cognitive deficiency in very preterm infants: the EPIPAGE prospective cohort. Acta Paediatr (2011) 1.75
Prolonged sedation and/or analgesia and 5-year neurodevelopment outcome in very preterm infants: results from the EPIPAGE cohort. Arch Pediatr Adolesc Med (2008) 1.74
Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther (2007) 1.74
Major hepatectomy for the treatment of complex bile duct injury. Ann Surg (2008) 1.74
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol (2007) 1.73
Neonatal and 5-year outcomes after birth at 30-34 weeks of gestation. Obstet Gynecol (2007) 1.72
Pancreas divisum is not a cause of pancreatitis by itself but acts as a partner of genetic mutations. Am J Gastroenterol (2011) 1.71
A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology (2009) 1.70
How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull (2009) 1.69
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol (2006) 1.67
Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol (2012) 1.66
High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis. Radiology (2011) 1.64
Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology (2012) 1.64
Reappraisal of central pancreatectomy a 12-year single-center experience. JAMA Surg (2014) 1.62
Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab (2013) 1.59
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol (2009) 1.58
Fetal sex and indicated very preterm birth: results of the EPIPAGE study. Am J Obstet Gynecol (2004) 1.58
Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.58
Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening: a longitudinal population-based cohort study. J Clin Endocrinol Metab (2011) 1.57
Liver packing during elective surgery: an option that can be considered. World J Surg (2011) 1.57
Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation. Hepatology (2002) 1.55
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology (2009) 1.55
Incidence and consequence of an hepatic artery injury in patients with postcholecystectomy bile duct strictures. Ann Surg (2003) 1.54
Staging of pancreatic head adenocarcinoma with spiral CT and endoscopic ultrasonography: an indirect evaluation of the usefulness of laparoscopy. Pancreatology (2004) 1.54
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology (2005) 1.54
Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery (2005) 1.54
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg (2012) 1.53
Cerebral palsy among very preterm children in relation to gestational age and neonatal ultrasound abnormalities: the EPIPAGE cohort study. Pediatrics (2006) 1.53
Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology (2008) 1.51